Metastatic Melanoma Survival Transformed by Targeted Therapy and Immunotherapy

Metastatic melanoma represents the most lethal form of cutaneous malignancy, and its incidence has been rising steadily for decades. While early-stage melanoma carries a survival rate approaching 94%, metastatic disease presents a substantially more complex clinical challenge. According to the National Cancer Institute, the incidence of metastatic melanoma was estimated at 0.9 per 100,000 between 2014 and 2018, with mucosal and ocular subtypes carrying especially poor prognoses.

This StatPearls review synthesizes current knowledge on the biology, risk stratification, genetic landscape, and treatment of metastatic melanoma. The article draws on established clinical data and guidelines from bodies including ASCO to present a comprehensive overview for practicing clinicians.

A key insight is that metastasis risk is directly tied to the depth of invasion and ulceration of the primary lesion. Importantly, even patients with clinically node-negative disease or negative sentinel lymph node biopsies can develop distant metastases, and complete lymph node dissection has not been shown to confer a survival advantage in node-positive patients. Rare cases of melanoma transmission via organ transplant highlight the possibility of early subclinical micrometastasis.

On the molecular level, copy number alterations, MITF amplification, TERT promoter mutations, and CDKN2A loss occur at higher frequencies in metastatic melanoma compared to primary tumors. CNS metastasis is particularly problematic, as the blood-brain barrier limits therapeutic access and contributes to high morbidity and mortality.

The most transformative development in this field is the shift from single-agent chemotherapy to combination targeted therapies and immunotherapies, which have markedly improved quality of life and overall survival. These advances underscore the importance of staying current with rapidly evolving treatment protocols in melanoma care.